Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

The stock's rise snapped a four-day losing streak.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Vertex Pharmaceuticals EVP Edward Atkinson sold 1,767 shares for $849,838 on Feb. 25, 2025. This transaction, conducted under ...

Vertex Pharmaceuticals has been attracting investor attention due to strong recent stock performance. The company's shares ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.